AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of OncoResponse.

    Client Virtual Booth

    ONCORESPONSE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    OncoResponse
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1124 Columbia Street Suite 300 Seattle, WA 98104
    Telephone
    Telephone
    206-805-1600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://oncoresponse.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oncoresponse/
    Twitter
    Twitter
    https://twitter.com/OncoResponse

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    OncoResponse Announces Initiation of Phase 1/2 Clinical Trial of OR502, Anti-LILRB2 Antibody, in Subjects with Advanced Cancer

    Details:

    OR502 a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2) antibody. It is being evaluated for the treatment of advanced solid tumors.


    Lead Product(s): OR502,Cemiplimab

    Therapeutic Area: Oncology Product Name: OR502

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 29, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    OncoResponse Awarded $13 Million in Funding from CPRIT to Advance Cancer Immunotherapy

    Details:

    The CPRIT award will support the advancement of OR502, a best-in-class anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2-mediated immune suppression, poised to move to IND and clinical studies.


    Lead Product(s): OR502

    Therapeutic Area: Oncology Product Name: OR502

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: CPRIT

    Deal Size: $13.0 million Upfront Cash: Undisclosed

    Deal Type: Funding May 18, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    OncoResponse Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy

    Details:

    The investment will support the advancement of OR502, a best-in-class anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2-mediated immune suppression, poised to move to IND and clinical studies.


    Lead Product(s): OR502

    Therapeutic Area: Oncology Product Name: OR502

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: RiverVest Venture Partners

    Deal Size: $14.0 million Upfront Cash: Undisclosed

    Deal Type: Financing May 18, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    OncoResponse Announces Clinical Supply Agreement with Regeneron to Evaluate OR2805 in Combination with Libtayo® (cemiplimab) in Patients with Advanced ...

    Details:

    The supply agreement will support the evaluation of Libtayo in combination with OR2805, a fully human monoclonal antibody identified from an elite cancer responder using OncoResponse’s proprietary B-cell discovery platform.


    Lead Product(s): OR2805,Cemiplimab

    Therapeutic Area: Oncology Product Name: OR2805

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement September 07, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    transo-pharm-handels-gmbh-m-2024-05-20

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search